Nexalin releases December 2025 investor presentation; cash $4.4M, no debt, warrants expired

Nexalin Technology, Inc.

Financial snapshot: Cash $4.4M, zero debt, 18.2M common shares, 22.3M fully diluted; warrants expired Sept 2025.
Gen-2 SYNC (15mA) in-clinic device and Gen-3 HALO at-home device with subscription model highlighted.
Regulatory progress: FDA De Novo strategy for Alzheimer's, insomnia; clearances in China, Brazil, Oman, Israel.
Clinical results claim 77% insomnia improvement, 74% depression improvement; Alzheimer's cognitive gains noted.
Go-to-market includes military TBI/PTSD advisory board with former NATO Supreme Commander and DoD official.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.